Leukotriene Modifiers
Verified · Oct 2026Prototype: montelukast
Leukotriene Modifiers are a class of medications used for long-term control of chronic asthma.
Leukotriene receptor antagonists — a once-daily oral option for asthma and allergic rhinitis. Recognizable by -lukast.
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 Leukotrienes — a different arm of asthma inflammation
Asthma isn’t just bronchospasm; it is inflammation. When mast cells and other immune cells are triggered, they release leukotrienes — inflammatory mediators built from arachidonic acid by the enzyme 5-lipoxygenase. Leukotrienes are potent: they cause bronchoconstriction, airway swelling (edema), and mucus — and they drive the sustained, allergic component of asthma that bronchodilators alone don’t touch.
This is a separate pathway from the β2-agonists (which relax muscle) and even from steroids (which broadly suppress inflammation). Leukotriene modifiers specifically switch off the leukotriene arm — useful as an add-on controller and especially in exercise-induced and allergy-driven asthma.
02 Two ways to block — receptor vs synthesis
The class works at two points. Montelukast and zafirlukast are leukotriene-receptor antagonists — they block the CysLT1 receptor so leukotrienes can’t deliver their message. Zileuton works upstream: it inhibits 5-lipoxygenase, so the leukotrienes are never made. Either way the leukotriene effect is silenced.
A key teaching point: these are controllers, not rescuers. They are taken daily to prevent symptoms and have no role in an acute attack — montelukast’s slow, oral onset can’t open a closing airway. A patient must keep their rescue inhaler for that.
03 The mental-health signal — a boxed warning
Montelukast and zafirlukast are generally well tolerated, which made a later safety signal notable: neuropsychiatric events — agitation, depression, sleep disturbance, and suicidal thoughts/behavior (including suicide). In 2020 the FDA added a boxed warning to montelukast after continued reports (including completed suicides), and now advises reserving it for allergic rhinitis only when other options fail. Zafirlukast and zileuton labels also warn about neuropsychiatric events, though not as a boxed warning.
Separately, zileuton and zafirlukast can be hepatotoxic, so liver enzymes are monitored with those agents. But the headline nursing point is to counsel patients and families to watch for and report mood or behavior changes.
Drug names
Indications
- Long-term control (prophylaxis) of chronic asthma — add-on therapy
- Prevention of exercise-induced bronchoconstriction
- Allergic rhinitis (montelukast — now reserved due to the boxed warning)
Mechanism of action
Montelukast and zafirlukast competitively block the cysteinyl leukotriene (CysLT1) receptor; zileuton inhibits 5-lipoxygenase, blocking leukotriene synthesis. Both reduce leukotriene-mediated bronchoconstriction, airway edema, and mucus — as daily controllers, not rescue agents.
Therapeutic effects — what you'll see working
Success is fewer symptoms and exacerbations over weeks of daily use, and prevention of exercise-induced attacks — never acute relief. Judge benefit over time, and confirm the patient still carries a rescue inhaler.
- Fewer asthma symptoms
- Blocking the leukotriene arm reduces daily bronchoconstriction, swelling, and mucus, lowering symptom frequency and rescue-inhaler use over weeks.
- Prevents exercise-induced bronchoconstriction
- Taken ahead of activity (or daily), it blunts the leukotriene surge that narrows airways during exercise.
- Eases allergic rhinitis
- The same leukotriene blockade reduces nasal allergy symptoms — though montelukast is now reserved for this use given its boxed warning.
Adverse effects
Montelukast and zafirlukast effects are mostly mild (headache, GI); the key risks are the neuropsychiatric boxed warning and, for zileuton/zafirlukast, hepatotoxicity.
Contraindications
Few absolute bars — the key precautions are the psychiatric history, hepatic disease (zileuton/zafirlukast), and the universal “not for acute attacks.”
When to hold
Assess before giving — these findings mean hold the dose and act.
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Common questions
What are Leukotriene Modifiers used for?
How do Leukotriene Modifiers work?
What are the serious side effects of Leukotriene Modifiers?
When should a nurse hold Leukotriene Modifiers, and what safety checks apply?
Conditions treated
See also
Relax airway smooth muscle to open the airways. β2-agonists are the core — watch for tachycardia and the LABA-monotherapy rule.
The daily anti-inflammatory controller for asthma — not a rescue. Rinse and spit after use to reduce the risk of thrush.
Block H1 receptors to relieve allergy symptoms. The key split: 1st-generation sedates, 2nd-generation doesn’t.
An older oral bronchodilator with a dangerously narrow therapeutic window — levels must be monitored.
OTC antitussives, expectorants, and decongestants. Know decongestant BP effects and the dextromethorphan interaction.
Prevent mast cells from releasing histamine — pure prophylaxis. Very safe, but useless in an acute attack.
Sources
- FDA — boxed warning for montelukast (serious mental-health side effects), 2020 — U.S. FDA
- Montelukast — leukotriene-receptor antagonism, indications, adverse effects — StatPearls (NCBI)
- Leukotriene Receptor Antagonists — class mechanism & monitoring — StatPearls (NCBI)
- SINGULAIR (montelukast) — boxed neuropsychiatric warning, prescribing information — DailyMed (NLM)
- Zafirlukast tablets — hepatotoxicity, contraindications — DailyMed (NLM)
- ZYFLO (zileuton) — 5-lipoxygenase, hepatic contraindication — DailyMed (NLM)
- The Role of the Body Clock in Asthma and COPD — evening dosing — PMC (open access)
- Drugs@FDA — leukotriene-modifier brand marketing status — U.S. FDA
Reviewed by Hae Suk Lee, RN
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.